
How to Invest in Coronavirus Vaccine Stocks
Just follow these three simple steps.
The Motley Fool’s live guide on what investors should do during the stock market crash and the COVID-19 pandemic.
We’ve created this page for all investors seeking advice on what they should be doing in this turbulent period. Our most important content can be found in the Editors' Picks, section.
We do believe this will all end up behind us, because we view investing as a long-term endeavor. Borrowing from Warren Buffett: "We have no idea -- and never have had -- whether the market is going to go up, down, or sideways in the near- or intermediate-term future." However, we firmly believe investors will be rewarded over the long term.
We suggest bookmarking this page as we will update our Editors' Picks periodically -- the Recent Articles section is a live feed of our latest thinking. Finally, we understand that many people are seeking epidemiological information on COVID-19. For that we strictly suggest visiting the information pages set up by the CDC and WHO.
For members of The Motley Fool's investing services, you can access all our Coronavirus market coverage at fool.com/premium after logging in.
Just follow these three simple steps.
Here's exactly how they could realistically pull it off.
The coronavirus pandemic will have a lasting impact on the nation's most important social program.
The ability to globally distribute a vaccine is as important as the vaccine itself. To the best-equipped victors go the spoils.
"Forever" may just be a great holding period for these two companies.
And it will soon soar even more thanks to the strong demand for Moderna's COVID-19 vaccine.
The biotech's growth prospects still appear to clearly outweigh its risks.
This issue won't affect just Ocugen.
It's a volatile stock right now. But the future for genomic testing looks bright.
Take a look at two of the most promising stocks on the market today.
The short answer: No.
The good news keeps on coming.
The biotech's messenger RNA platform is promising. But some investors could have qualms about its current valuation.
This straggler in the vaccine race is still facing some struggles -- but there are a couple of bright spots.
The biotech certainly has plenty of COVID-19 candidates in the hopper.
Here are the short- and long-term answers.
There's plenty to like about both of these high-flying biotech stocks.
The two big drugmakers' vaccine fortunes recently went in opposite directions.
Here's why you might want to -- and why it might not be such a great idea.
There's continued momentum from the drugmaker's big news announced earlier this month.
Casinos still face strong headwinds, but this resort operator has one major defense against them.
But this development could be enormously important in fighting COVID-19.
J&J's new vaccine could be important in ending the pandemic.
It's simply not an apples-to-apples comparison.